Out Of The Blocks, March 2012

Brief profiles of these recently formed companies: Achelios Therapeutics, EternoGen, QI Healthcare, Retrophin, Synchroneuron and TeraBAT.

Achelios Therapeutics LLC

c/o Exodos Life Science Partners

1340 Environ Way

Chapel Hill, NC 27517

Phone: [phone]

E-Mail: [email protected]

Achelios Therapeutics will develop a topical treatment for migraine and peripheral pain. The company spun out from Exodus Life Science Partners, a pharma development firm that advances reformulated compounds through the 505(b)(2) process. Exodos president and CEO Crist Frangakis, PhD, also leads Achelios, which has raised $1.9 million of a proposed $3 million first round.

EternoGen LLC

1415 Risen Star Court

Columbia, MO 65202

Phone: [phone]

E-Mail:[email protected]

Web Site: www.eternogen.com

University of Missouri spin-out EternoGen is developing a novel collagen filler for cosmetic and other applications. The company says its NanoScaffolding platform links gold nanoparticles to collagen, creating a long-lasting filler that has antioxidant, anti-inflammatory and antimicrobial properties, and less than a 1% change in the natural formulation of collagen. Luis R. Jimenez is EternoGen’s CEO.

QI Healthcare Systems LLC

c/o CincyTech

30 West 3rd Street

6th Floor

Cincinnati, OH 45202

Phone: [phone]

E-Mail: [email protected]

Web Site: www.qihealthcare.com

QI Healthcare was formed to commercialize technology developed at Cincinnati Children’s Hospital Medical Center. Its first product, the Surgical Outcomes Collection System, aggregates data from various hospital systems and electronic health records, enabling institutions to more easily identify opportunities to improve patient care. Former WebMD exec John Atkinson is CEO of the start-up, which has raised $400,000 from Cincinnati Children’s and CincyTech.

Retrophin Inc.

330 Madison Avenue

6th Floor

New York, NY 10017

Phone: [phone]

Email: [email protected]

Web Site: www.retrophin.com

Retrophin has licensed a small molecule angiotensin/endothelin receptor antagonist from Ligand and will commercialize it for orphan indications of severe kidney diseases, as well as resistant hypertension and diabetic nephropathy. The start-up’s lead internally discovered compound is a protein replacement therapy for Duchenne muscular dystrophy. Chairman and CEO Martin Shkreli is also chief investment officer at MSMB Capital Management, which led Retrophin’s Series A round.

Synchroneuron Inc.

c/o Accellient Partners

1000 Winter Street Suite 2000 NorthWaltham, MA 02451Phone: [phone]

E-Mail: [email protected]

Synchroneuron is developing therapeutics for movement disorders, starting with a reformulation of an existing drug to treat tardive dyskinesia. Company founder Barry Fogel, MD, invented the oral drug in the 1990s and briefly licensed it to Somaxon. Accellient Partners CEO William Kerns, DVM, is Synchroneuron’s interim CEO. The start-up raised a $6 million Series A round from Morningside Technology Ventures.

TeraBAT Inc.

2400 Trade Centre Avenue

Longmont, CO 80503

Phone: [phone]

E-Mail: [email protected]

Web Site: www.terabat.com

TeraBAT employs electromagnetic waves in the terahertz range to rapidly detect molecules in exhaled breath that are indicators of both acute and chronic disease. It will commercialize the technology for real-time hospital-based point-of-care diagnostics and treatment monitoring. TeraBAT licensed its technology from the University of Massachusetts, Amherst, where it was invented by founder Eyal Gerecht, PhD.